qRT-PCR (real-time reverse transcription-PCR) has become the benchmark for the detection
and quantification of RNA targets and is being utilized increasingly in novel clinical …

Detection of minimal residual disease (MRD) has prognostic value in many hematologic
malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic …

Small interfering RNAs (siRNAs) were designed to target the bcr-abl oncogene, which
causes chronic myeloid leukemia (CML) and bcr-abl–positive acute lymphoblastic leukemia …

Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …

Although targeting the BCR-ABL tyrosine kinase activity by imatinib mesylate has rapidly
become first-line therapy in chronic myeloid leukemia (CML), drug resistance suggests that …

PRAME (Preferentially expressed antigen of melanoma) has been previously identified as a
melanoma antigen recognized by cytotoxic T cells (CTLs) and found to be expressed in a …

The degree of tumor load reduction after therapy is an important prognostic factor for
patients with CML. Conventional metaphase analysis has been considered to be the 'gold …

Abstract Analysis of donor chimerism has become a routine method for the documentation of
engraftment after allogeneic hematopoietic stem cell transplantation (HSCT). In recent years …

Imatinib mesylate (trade name Glivec® or Gleevec) is emerging as an important therapy in
the management of chronic myeloid leukaemia (CML). It is clinically useful to monitor the …

A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based …